Targeted and cytotoxic therapy in coordinated sequence (TACTICS): Erlotinib, bevacizumab, and standard chemotherapy for nonsmall-cell lung cancer, a phase II trial

Ezra E.W. Cohen, Janakiraman Subramanian, Feng Gao, Livia Szeto, Mark Kozloff, Leonardo Faoro, Theodore Karrison, Ravi Salgia, Ramaswamy Govindan, Everett E. Vokes

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background: This trial focused on optimally combining existing targeted therapies and cytotoxic chemotherapy in the treatment of unselected patients with advanced nonsmall-cell lung cancer (NSCLC). Methods: Patients with previously untreated advanced-stage nonsquamous NSCLC were eligible for this trial. In module A, patients received up to 4 cycles of erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks. Patients then received carboplatin (AUC = 6), paclitaxel 200 mg/m2, and bevacizumab 15 mg/kg for 4 cycles in module B. Patients who did not have progressive disease in module A received maintenance erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks in module C. Results: Forty-eight patients were enrolled in this multicenter phase II trial. Most patients were male (62.5%) and white (77.1%) with stage IV disease (93.8%) and adenocarcinoma histologic type (66.7%). The overall response rate in module A was 10.4%, in module B it was 15.1%, and in module C it was 5.5%. The study achieved its primary endpoint, with a nonprogression rate of 45.8% in module A. The median overall survival (OS) was 12.6 months. Conclusion: The novel systemic therapy regimen is feasible in patients with advanced NSCLC. However there is no further role for developing this regimen in unselected patients with NSCLC.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalClinical Lung Cancer
Volume13
Issue number2
DOIs
StatePublished - Mar 1 2012

Keywords

  • Bevacizumab
  • EGFR TK mutation
  • Erlotinib
  • NSCLC advanced stage

Fingerprint Dive into the research topics of 'Targeted and cytotoxic therapy in coordinated sequence (TACTICS): Erlotinib, bevacizumab, and standard chemotherapy for nonsmall-cell lung cancer, a phase II trial'. Together they form a unique fingerprint.

  • Cite this